Physician

Jarred T Burkart, MD

According to 2025 Medicare claims, Jarred Burkart, MD (NPI: 1205102001) practices internal medicine in the Columbus, OH market, with the plurality of this provider's patient population coming from Franklin, OH. This provider's primary affiliated billing organization is COLUMBUS ONCOLOGY ASSOCIATES INC (NPI: 1790875656; TIN: 311211874) and primary practice location at 43214-4359.

Burkart's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 457 traditional Medicare patients, billed 104,222 HCPCS/CPT codes, and received $2,013,665 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,459 prescription claims across 193 beneficiaries totaling $4,320,650 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 12 claims. Open Payments data shows 3 records totaling $349. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $7,230 to $2,013,665. Similarly, Part D prescription costs have moved sharply higher in recent years, from $35,645 to $4,320,650. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $6,102 to $686.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	50	120	$7,230
2016	66	178	$11,384
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	90	8,485	$170,087
2020	191	31,722	$549,157
2021	328	54,477	$845,807
2022	422	83,150	$1,758,979
2023	413	69,245	$1,379,361
2024	457	104,222	$2,013,665

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	54	330	$35,645
2016	14	46	$12,337
2017	17	46	$2,292
2018	27	74	$2,659
2019	45	160	$90,487
2020	91	457	$1,160,456
2021	136	845	$1,237,766
2022	177	1,219	$2,584,923
2023	187	1,274	$3,019,575
2024	193	1,459	$4,320,650

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	91	$5,165
2016	N/R	12	$767
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	14	$967
2023	N/R	12	$733
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	74	189	$130
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	229	647	$88
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	108	143	$57
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	65	136	$44
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	251	628	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	50	1,400	$995,082
Verzenio	Abemaciclib	31	868	$494,601
Lenalidomide	Lenalidomide	33	924	$463,502
Lenvima	Lenvatinib Mesylate	17	510	$413,664
Ojjaara	Momelotinib Dihydrochloride	12	360	$340,228

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	3	$349	Adaptive Biotechnologies Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jarred T. Burkart, MD?

Tedicare shows public-source Medicare data for Jarred T. Burkart, MD (NPI 1205102001), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jarred T. Burkart, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Jarred T. Burkart, MD?

Jarred T. Burkart, MD is linked to COLUMBUS ONCOLOGY ASSOCIATES INC (billing NPI 1790875656) in the available physician profile data.

Does Jarred T. Burkart, MD have Open Payments data?

Jarred T. Burkart, MD has 3 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.